
Please try another search
(Reuters) - Moderna (NASDAQ:MRNA) Inc said on Sunday it has been told that the U.S. Food and Drug Administration will require additional time to complete its assessment of the company's COVID-19 vaccine for use in adolescents aged 12 to 17 years.
The FDA informed Moderna that the review may not be completed before January 2022, the company said in a statement, dealing a potential setback to the timing of an emergency use authorization (EUA) for that age group.
Moderna Chief Executive Stephane Bancel told Reuters last week https://www.reuters.com/business/healthcare-pharmaceuticals/exclusive-moderna-covid-19-shot-could-start-being-used-children-teens-within-2021-10-27 that based on conversations with the agency, he believed the vaccine would be authorized for those 12 to 17 in the next few weeks.
The U.S. biotech company said it was told late on Friday that the FDA needed the additional time to evaluate recent international analyses of the risk of a type of heart inflammation called myocarditis after vaccination, a rare side effect that has primarily affected young males.
Moderna said it is conducting its own review of new external analyses on the increased myocarditis risk in those less than 18 years of age as they become available.
Moderna applied for U.S. authorization of its shot for those aged 12 to 17 in June.
Americans of those ages are eligible for the similar COVID-19 vaccine from Pfizer Inc (NYSE:PFE) and partner BioNTech SE (NASDAQ:BNTX) after it was cleared by the FDA and Centers for Disease Control and Prevention in May.
Moderna also said it will delay filing its request for an EUA for a half strength 50-microgram dose of the vaccine for children ages 6 to 11 while the FDA completes its review of the 12-17 filing.
By Hyunjoo Jin and Akash Sriram (Reuters) - Tesla (NASDAQ:TSLA) Inc delivered 17.9% fewer electric vehicles in the second quarter from the previous quarter, as China's COVID...
MADRID (Reuters) - Spain-based cabin crew at Ryanair plan to strike for 12 days this month to demand better working conditions, the USO (NYSE:USO) and SICTPLA unions said on...
Tesla (NASDAQ:TSLA) said it delivered 254,695 electric vehicles (EVs) in the second quarter, an increase of 27% on a year-to-year basis. Still, the reported number came below the...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.